Keio University · 의학
Hirofumi Kawakubo 교수의 연구실은 유방암 및 식도암을 중심으로 한 암 생물학과 치료 반응 예측에 초점을 맞추고 있습니다. 특히 BTG2 단백질의 세포 내 국소화 및 세포주기 억제 기능에 대한 기전 연구를 통해 암 발생 메커니즘을 규명하고 있으며, 신재생의학적 관점에서의 암 치료 전략 개발에도 기여하고 있습니다. 또한, 수술 전 화학요법(예: DCF 요법)의 임상적 효과와 예후 분류 기준의 실생활 데이터 기반 검증을 통해 개인화된 암 치료 전략을 모색하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
The B-cell translocation gene-2 (BTG2) is present in the nuclei of epithelial cells in many tissues, including the mammary gland where its expression is regulated during glandular proliferation and differentiation in pregnancy. In immortalized mammary epithelial cells and breast cancer cells, BTG2 protein localized predominantly to the nucleus and cytoplasm, respectively. The highly conserved domains (BTG boxes A, B, and C) were required for regulating localization, suppression of cyclin D1 and
Neoadjuvant DCF therapy showed a remarkable survival advantage in surgically resectable ESCC patients, especially in patients who were 75 years old or younger. The current real-world evidence will encourage recommendations for DCF as a standard regimen in neoadjuvant chemotherapy-based treatment strategy for ESCC.
It was found that postoperative recurrence in responders occurred in the regional field mostly as a solitary lesion without the distant failure, indicating that the residual tumor cells can be eliminated by additional chemoradiotherapy.
The prognostic value of classification using pStage and the pathological response was successfully validated using real-world data in Japan. This result would guide appropriate treatment for patients with esophageal squamous cell carcinoma who received neoadjuvant chemotherapy followed by esophagectomy.
